Anocca
  • About us
    • Introduction
    • Company leadership
  • Technologies
    • Introduction
    • Challenge
    • Engineered Immunity
    • Differentiation
    • Manufacturing
  • Pipeline
  • Partnering
  • Newsroom
    • Press releases
    • Anocca in the news
    • Reports & Regulatory press releases
  • Event calendar
  • Careers
Select Page

Mobile menu footer

Aug 6, 2020 | Uncategorized

Anocca AB

General enquires
info@anocca.com

Business Development & Partnering
bd@anocca.com

Science & Technology
sci@anocca.com

Visit us on LinkedIn

< Back to newsroom

Latest news

  • Press release Dec 21, 2022

    Anocca säkrar 25 miljoner euro från Europeiska investeringsbanken (EIB) för att stödja klinisk utveckling av nästa generations T-cellsterapier för cancer

    Södertälje, 21 december 2022 – Anocca, ett helt integrerat bioteknikföretag för utveckling av T-cellsbehandlingar, meddelade …

    Read more »

  • Press release Dec 21, 2022

    Anocca secures EUR 25 million from the European Investment Bank (EIB) to support clinical development of next-generation T-cell therapies for cancer

    Södertälje, Sweden, 21 December 2022 – Anocca, a fully integrated cell therapy biotechnology company, today …

    Read more »

  • Press release Apr 7, 2022

    Renowned Immunotherapy Expert Dr. Michael Kalos joins Anocca’s Scientific Advisory Board

    Södertälje, Sweden, 7th April 2022 – Anocca, a biotechnology company using its precision biology platforms …

    Read more »

Anocca AB

Forskargatan 20C
151 36 Södertälje, Sweden
+46 (0)8 410 807 50

info@anocca.com

Show on map

Direct Contact

Business Development & Partnering
bd@anocca.com

Science & Technology
sci@anocca.com

Talent & Recruitment
jobs@anocca.com

Visit us on LinkedIn

Copyright © 2020 Anocca AB
Registration number 556946-2384

Anocca Privacy Policy

  • Anocca AB

    General enquires
    info@anocca.com

    Business Development & Partnering
    bd@anocca.com

    Science & Technology
    sci@anocca.com

    Visit us on LinkedIn